It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Rationale
COVID-19 ARDS could differ from typical forms of the syndrome.
Objective
Pulmonary microvascular injury and thrombosis are increasingly reported as constitutive features of COVID-19 respiratory failure. Our aim was to study pulmonary mechanics and gas exchanges in COVID-2019 ARDS patients studied early after initiating protective invasive mechanical ventilation, seeking after corresponding pathophysiological and biological characteristics.
Methods
Between March 22 and March 30, 2020 respiratory mechanics, gas exchanges, circulating endothelial cells (CEC) as markers of endothelial damage, and D-dimers were studied in 22 moderate-to-severe COVID-19 ARDS patients, 1 [1–4] day after intubation (median [IQR]).
Measurements and main results
Thirteen moderate and 9 severe COVID-19 ARDS patients were studied after initiation of high PEEP protective mechanical ventilation. We observed moderately decreased respiratory system compliance: 39.5 [33.1–44.7] mL/cmH2O and end-expiratory lung volume: 2100 [1721–2434] mL. Gas exchanges were characterized by hypercapnia 55 [44–62] mmHg, high physiological dead-space (VD/VT): 75 [69–85.5] % and ventilatory ratio (VR): 2.9 [2.2–3.4]. VD/VT and VR were significantly correlated: r2 = 0.24, p = 0.014. No pulmonary embolism was suspected at the time of measurements. CECs and D-dimers were elevated as compared to normal values: 24 [12–46] cells per mL and 1483 [999–2217] ng/mL, respectively.
Conclusions
We observed early in the course of COVID-19 ARDS high VD/VT in association with biological markers of endothelial damage and thrombosis. High VD/VT can be explained by high PEEP settings and added instrumental dead space, with a possible associated role of COVID-19-triggered pulmonary microvascular endothelial damage and microthrombotic process.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France; AH-HP, Georges Pompidou European Hospital, Intensive Care Unit and Biosurgical Research Lab (Carpentier Foundation), Paris, France (GRID:grid.414093.b)
2 AH-HP, Georges Pompidou European Hospital, Université de Paris, Intensive Care Unit, Paris, France (GRID:grid.414093.b)
3 Université de Paris, PARCC, INSERM, Paris, France (GRID:grid.410511.0) (ISNI:0000 0001 2149 7878); AP–HP, Georges Pompidou European Hospital, Emergency Department, Paris, France (GRID:grid.414093.b)
4 AP-HP, Georges Pompidou European Hospital, Université de Paris, Plastic Surgery Department, Paris, France (GRID:grid.414093.b)
5 AP-HP, Georges Pompidou European Hospital, Université de Paris, Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), Paris, France (GRID:grid.414093.b)
6 Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France (GRID:grid.414093.b); AH-HP, Georges Pompidou European Hospital, Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Paris, France (GRID:grid.414093.b)
7 AP–HP, Georges Pompidou European Hospital, Emergency Department, Paris, France (GRID:grid.414093.b)
8 Université de Paris, PARCC, INSERM, Paris, France (GRID:grid.410511.0) (ISNI:0000 0001 2149 7878); AP-HP, Georges Pompidou European Hospital, Vascular Medicine Department, Paris, France (GRID:grid.414093.b)